Drug intelligence / Profile preview

VTX-PID

Development stage: Unknown
Lead developer: Vivet Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

VTX-PID is a novel investigational technology developed by Vivet Therapeutics aimed at depleting neutralizing antibodies (NAbs) specific to a given adeno-associated virus (AAV) serotype. This depletion allows for improved AAV vector transduction, which is critical in gene therapy applications where pre-existing or induced NAbs can limit the efficacy of AAV-based gene delivery. VTX-PID is currently advancing in a Phase 1 clinical study targeting subjects positive for NAbs, with initial results already obtained and further data expected in 2025. The technology supports enhanced liver transduction in animal models with NAbs and is part of Vivet Therapeutics' broader pipeline focused on rare inherited liver metabolic diseases using recombinant AAV vectors[1][2][3][4][7].

Other names: VTX-PID

Beyond the preview

Go deeper on VTX-PID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX-PID.

Explore the full profile